Antigenics Claims Skin Cancer Advances (AP)


AP - Biotech company Antigenics Inc. said Monday that preliminary data from a late-stage clinical trial suggests that its Oncophage cancer vaccine extended the survival of advanced skin cancer patients by about 8 months compared with standard therapies.